Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8210907 | 0.89 | KMT2A (0.68) | KMT2AALDH1A1CYP1A2CYP2C9TSHR | |
| SCHEMBL69684 | 0.87 | NSD2 (0.63) | KMT2AALDH1A1HPGDMAPTTDP1 | |
| SCHEMBL8673010 | 0.85 | NSD2 (0.61) | KMT2AALDH1A1HPGDMAPTTDP1 | |
| SCHEMBL28168705 | 0.85 | NSD2 (0.61) | KMT2AALDH1A1HPGDMAPTTDP1 | |
| SCHEMBL5684962 | 0.85 | KMT2A (0.51) | KMT2AALDH1A1CYP1A2CYP2C9TSHR | |
| SCHEMBL10664572 | 0.83 | PARP10 (0.65) | KMT2AALDH1A1SMN1; SMN2MAPTTDP1 | |
| SCHEMBL9368330 | 0.83 | MRGPRX4 (0.76) | ALDH1A1SMN1; SMN2PARP10NPC1RAB9A | |
| SCHEMBL4798881 | 0.82 | KMT2A (0.49) | KMT2AALDH1A1CYP1A2CYP2C9TSHR | |
| SCHEMBL4797877 | 0.82 | KMT2A (0.49) | KMT2AALDH1A1CYP1A2CYP2C9TSHR | |
| SCHEMBL5488350 | 0.81 | SMN1; SMN2 (0.61) | ALDH1A1CYP1A2TSHRGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112047917-B | Xanthohumol derivative and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2023-10-31 | — | — | CN | disclosed |
| CN-108517022-A | For the ingredient of solid catalyst and its catalyst of olefinic polymerization and application | 北京利和知信科技有限公司 | 2018-09-11 | — | — | CN | disclosed |
| CN-108517021-A | A kind of ingredient of solid catalyst, catalyst and its application being suitable for producing broad molecular weight distribution polymers | 北京利和知信科技有限公司 | 2018-09-11 | — | — | CN | disclosed |
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8853207-B2 | Heterocyclic pyrazole compounds, method for preparing the same and use thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-10-07 | — | — | US | disclosed |
| US-20130274255-A1 | HETEROCYCLIC PYRAZOLE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-10-17 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274255-A1 | HETEROCYCLIC PYRAZOLE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF | RET, FLT3, FGFR1 | KMT2A 1760/4885ALDH1A1 1491/4885CYP1A2 240/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | KMT2A 1384/4885ALDH1A1 3901/4885CYP1A2 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.